These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18615150)

  • 1. Modelling anxiety in humans for drug development.
    Siepmann M; Joraschky P
    Curr Neuropharmacol; 2007 Mar; 5(1):65-72. PubMed ID: 18615150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The age of anxiety: role of animal models of anxiolytic action in drug discovery.
    Cryan JF; Sweeney FF
    Br J Pharmacol; 2011 Oct; 164(4):1129-61. PubMed ID: 21545412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models of anxiety and anxiolytic drug action.
    Treit D; Engin E; McEown K
    Curr Top Behav Neurosci; 2010; 2():121-60. PubMed ID: 21309109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of anxiety and benzodiazepine actions.
    Iversen SD
    Arzneimittelforschung; 1980; 30(5a):862-8. PubMed ID: 6106486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of human experimental anxiety.
    Graeff FG; Parente A; Del-Ben CM; Guimarães FS
    Braz J Med Biol Res; 2003 Apr; 36(4):421-32. PubMed ID: 12700819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical test of the hippocampal theta model of anxiolytic drug action.
    Yeung M; Treit D; Dickson CT
    Neuropharmacology; 2012 Jan; 62(1):155-60. PubMed ID: 21723303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.
    Millan MJ
    Ther Adv Psychopharmacol; 2022; 12():20451253221105128. PubMed ID: 35795687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models of 'anxiety': where next?
    Rodgers RJ
    Behav Pharmacol; 1997 Nov; 8(6-7):477-96; discussion 497-504. PubMed ID: 9832964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin Conductance Responses and Neural Activations During Fear Conditioning and Extinction Recall Across Anxiety Disorders.
    Marin MF; Zsido RG; Song H; Lasko NB; Killgore WDS; Rauch SL; Simon NM; Milad MR
    JAMA Psychiatry; 2017 Jun; 74(6):622-631. PubMed ID: 28403387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a psychophysiological model of classical fear conditioning in anxious patients.
    Ashcroft KR; Guimarães FS; Wang M; Deakin JF
    Psychopharmacology (Berl); 1991; 104(2):215-9. PubMed ID: 1876666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A way forward for anxiolytic drug development: Testing candidate anxiolytics with anxiety-potentiated startle in healthy humans.
    Grillon C; Ernst M
    Neurosci Biobehav Rev; 2020 Dec; 119():348-354. PubMed ID: 33038346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics of the anxiolytic action of benzodiazepine and GABA derivatives on experimentally modelled anxiety states].
    Talalaenko AN; Zin'kovskaia LIa
    Farmakol Toksikol; 1988; 51(4):20-2. PubMed ID: 2903833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of buspirone with diazepam and fluvoxamine on aversive classical conditioning in humans.
    Hellewell JS; Guimaraes FS; Wang M; Deakin JF
    J Psychopharmacol; 1999; 13(2):122-7. PubMed ID: 10475716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is aversive learning a marker of risk for anxiety disorders in children?
    Craske MG; Waters AM; Lindsey Bergman R; Naliboff B; Lipp OV; Negoro H; Ornitz EM
    Behav Res Ther; 2008 Aug; 46(8):954-67. PubMed ID: 18539262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress.
    Yamaguchi T; Tsujimatsu A; Kumamoto H; Izumi T; Ohmura Y; Yoshida T; Yoshioka M
    J Ethnopharmacol; 2012 Sep; 143(2):533-9. PubMed ID: 22819689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.
    Barrett JE; Vanover KE
    Psychopharmacology (Berl); 1993; 112(1):1-12. PubMed ID: 7870996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant treatment in anxiety disorders.
    Bespalov AY; van Gaalen MM; Gross G
    Curr Top Behav Neurosci; 2010; 2():361-90. PubMed ID: 21309117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loop diuretics have anxiolytic effects in rat models of conditioned anxiety.
    Krystal AD; Sutherland J; Hochman DW
    PLoS One; 2012; 7(4):e35417. PubMed ID: 22514741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of anxiety in transgenic mice.
    Weiss SM; Lightowler S; Stanhope KJ; Kennett GA; Dourish CT
    Rev Neurosci; 2000; 11(1):59-74. PubMed ID: 10716656
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.